Carbohydrate metabolism disorders in patients with rheumatoid arthritis and ankylosing spondylitis – impact of the severity of the inflammatory process and disease activity
More details
Hide details
Submission date: 2013-05-05
Final revision date: 2013-07-31
Acceptance date: 2013-08-19
Online publication date: 2014-03-23
Publication date: 2014-04-30
Reumatologia 2014;52(1):62-68
Carbohydrate metabolism disorders are much more common among rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients than in the general population. Chronic inflammation related to insulin resistance underlies the pathogenic mechanism of both rheumatoid disorders and diabetes. Interleukin-6 (IL-6) and tumour necrosis factor α (TNF-α) as well as substances produced by adipose tissue, including free fatty acids, leptin, resistin, visfatin and adiponectin, play a crucial role in the development of insulin resistance. The data show that there is a strong relationship between high level of inflammatory markers and insulin resistance and higher risk of diabetes in patients with inflammatory rheumatic diseases. However, still other markers of disease activity are being sought, which could help to identify the patients with highest risk of impaired glucose tolerance. In the paper a literature overview has been presented concerning the assessment of risk of carbohydrate disorders among RA and AS patients and the disorders’ relationship with the intensity of non-specific inflammation and the disease activity.
Peters MJ, Visman I, Nielen MM, et al. Ankylosing spondylitis: a risk factor for myocardial infarction. Ann Rheum Dis 2010; 69: 579-581.
Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum 2005; 52: 402-411.
Sieradzki J. Cukrzyca i zespół metaboliczny. W: Interna Szczeklika. Podręcznik chorób wewnętrznych. Jarząb B (red.). Medycyna Praktyczna, Kraków 2012; 1322-1325.
Sieradzki J. Cukrzyca. Tom I. Via Medica, Gdańsk 2007; 251-291.
Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353: 1649-1652.
Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes. Diabetes 2003; 52: 1799-1805.
Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes – results of the Prospective Population-Based European Prospective Investigation into Cancer and Nutrition (EPIC) – Potsdam Study. Diabetes 2003; 52: 812-817.
Hu FB, Meigs JB, Li TY, et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700.
Chase HP, Cooper S, Osberg I, et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes 2004; 53: 2569-2573.
Han C, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-2172.
Simard JF, Mittleman MA. Prevalent rheumatoid arthritis and diabetes mellitus among NHANES III participant aged 60 and older. J Rheumatol 2007; 34: 469-473.
Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of dia­betes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010; 69: 2114-2117.
Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common commorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011; 63: 550-556.
da Cunha VR, Brenol CV, Brenol JC, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol 2012; 41: 186-191.
Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appriopriate usage. Am J Physiol Endocrinol Metab 2008; 294: E15-26.
Hirabara SM, Gorjão R, Vinolo MA, et al. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol 2012; 2012: 379024.
Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-αlpha – and obesity-induced insulin resistance. Science 1996; 271: 665-668.
Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272: 971-976.
de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008; 582: 97-105.
Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res 2011; 63: 512-521.
Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012; 14: R141.
Oncül O, Top C, Ozkan S, et al. Serum interleukin 2 levels in patients with rheumatoid arthritis and correlation with insulin sensitivity. J Int Med Res 2002; 30: 386-390.
Tuncman G, Hirosumi J, Solinas G, et al. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A 2006; 103: 10741-10746.
Chung CP, Oeser A, Solus JF, et al. Inflammation associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanism. Arthritis Rheum 2008; 58: 2105-2112.
Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic intervention. Circulation 2008; 117: 3238-3249.
Rho YH, Solus J, Sokka T, et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009; 60: 1906-1914.
Wiland P, Madej M, Szmyrka-Kaczmarek M. Monitorowanie stanu pacjenta w chorobach reumatycznych. Górnicki Wydawnictwo Medyczne, Wrocław 2008; 1-29.
Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2765-2775.
Wendling D, Racadot E, Augé B, Toussirot E. Soluble intercellular adhesion molekule 1 in spondylarthropathies. Clin Rheumatol 1998; 17: 202-204.
Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patents with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67: 511-517.
Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-766.
de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid protein for patent selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009; 61: 1484-1490.
Visvanathan S, van der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and association with bone mineral density in patent with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 175-182.
Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis 2011; 71: 674-680.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top